Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Published:2016-10-04 Issue:4 Volume:52 Page:512-519
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Ikeda Kenji,Kudo Masatoshi,Kawazoe Seiji,Osaki Yukio,Ikeda Masafumi,Okusaka Takuji,Tamai Toshiyuki,Suzuki Takuya,Hisai Takashi,Hayato Seiichi,Okita Kiwamu,Kumada Hiromitsu

Funder

Eisai Inc

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-016-1263-4.pdf

Reference28 articles.

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.

2. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354–60.

3. Bertino G, Demma S, Ardiri A, et al. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693.

4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

Cited by 295 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

2. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. A real-world drug safety surveillance study of lenvatinib from the FAERS database;Expert Opinion on Drug Safety;2024-08-21

4. Clinical Characteristics of 34 Cases Diagnosed as Thymic Carcinoma in Our Institution;Haigan;2024-08-20

5. Design, Synthesis and Evaluation of a Novel Teoptinib Derivative as an Effective Anti-hepatocellular Carcinoma Agent;Current Pharmaceutical Design;2024-08